Literature DB >> 23020519

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.

Ivan Spasojevic1, Ligia R S da Costa, Mitchell E Horwitz, Gwynn D Long, Keith M Sullivan, John P Chute, Cristina Gasparetto, Ashley Morris, Nelson J Chao, David A Rizzieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23020519      PMCID： PMC3791921          DOI： 10.3109/07357907.2012.726386

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  12 in total

1.  Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.

Authors:  R Beri; S Chunduri; K Sweiss; D J Peace; C Mactal-Haaf; L C Dobogai; S Shord; J G Quigley; Y H Chen; N Mahmud; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2009-06-22       Impact factor: 5.483

2.  Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Authors:  J T Slattery; R A Clift; C D Buckner; J Radich; B Storer; W I Bensinger; E Soll; C Anasetti; R Bowden; E Bryant; T Chauncey; H J Deeg; K C Doney; M Flowers; T Gooley; J A Hansen; P J Martin; G B McDonald; R Nash; E W Petersdorf; J E Sanders; G Schoch; P Stewart; R Storb; K M Sullivan; E D Thomas; R P Witherspoon; F R Appelbaum
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

Review 3.  Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Authors:  J S McCune; J P Gibbs; J T Slattery
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

4.  Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.

Authors:  B S Andersson; T Madden; H T Tran; W W Hu; K G Blume; D S Chow; R E Champlin; W P Vaughan
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

5.  Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.

Authors:  R H Matthews; M Emami; D G Connaghan; H K Holland; L E Morris
Journal:  Bone Marrow Transplant       Date:  2007-02-26       Impact factor: 5.483

6.  Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.

Authors:  Ederson Oliveira dos Reis; Rosane Vianna-Jorge; Guilherme Suarez-Kurtz; Edson Luiz da Silva Lima; Débora de Almeida Azevedo
Journal:  Rapid Commun Mass Spectrom       Date:  2005       Impact factor: 2.419

7.  Association of busulfan area under the curve with veno-occlusive disease following BMT.

Authors:  S P Dix; J R Wingard; R E Mullins; I Jerkunica; T G Davidson; C E Gilmore; R C York; L S Lin; S M Devine; R B Geller; L T Heffner; C D Hillyer; H K Holland; E F Winton; R Saral
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

Review 8.  Therapeutic drug monitoring of busulfan in transplantation.

Authors:  J A Russell; S B Kangarloo
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

Authors:  L B Grochow
Journal:  Semin Oncol       Date:  1993-08       Impact factor: 4.929

10.  Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.

Authors:  J T Slattery; J E Sanders; C D Buckner; R L Schaffer; K W Lambert; F P Langer; C Anasetti; W I Bensinger; L D Fisher; F R Appelbaum
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483
View more
  2 in total

1.  Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Authors:  Erika Watanabe; Takuro Nishikawa; Kazuro Ikawa; Hiroki Yamaguchi; Takanari Abematsu; Shunsuke Nakagawa; Koichiro Kurauchi; Yuichi Kodama; Takayuki Tanabe; Yuichi Shinkoda; Kazuaki Matsumoto; Yasuhiro Okamoto; Yasuo Takeda; Yoshifumi Kawano
Journal:  Int J Hematol       Date:  2015-08-05       Impact factor: 2.490

2.  An LC-MS Assay with Isocratic Separation and On-line Solid Phase Extraction to Improve the Routine Therapeutic Drug Monitoring of Busulfan in Plasma.

Authors:  Cristiano Ialongo; Alessia Francesca Mozzi; Sergio Bernardini
Journal:  J Med Biochem       Date:  2017-04-22       Impact factor: 3.402
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.